Cancer Control最新文献

{"title":"Impact of a Nurse-Led Cancer Pain Management Model on Breakthrough Pain and Patient Satisfaction: A Quasi-Experimental Before-After Study.","authors":"Jinpeng Jiang, Yamei Wu, Xunya Xiong, Zaiyu Huang","doi":"10.1177/10732748261472063","DOIUrl":"10.1177/10732748261472063","url":null,"abstract":"<p><p>IntroductionCancer pain is one of the most debilitating sequelae of cancer, and reducing this symptom burden benefits patients, nurses, and the nursing profession, especially in the care of breakthrough cancer pain (BTCP). This study aimed to assess the clinical application effectiveness of advanced nursing practices in a nurse-led cancer pain management model.MethodsThis was a non-randomized before-after quasi-experimental study. Using the convenience sampling method, 116 patients experiencing cancer pain who were admitted to tertiary comprehensive hospitals in the southern Hubei region from 2020 to 2021 were selected as the control group, and 104 patients experiencing cancer pain who were admitted from 2022 to 2025 were selected as the intervention group. A full process management model for cancer pain was implemented in the intervention group, whereas the control group did not receive the intervention. Both groups were followed-up for 6 months to compare the average pain score, incidence of BTCP, and satisfaction with pain control.ResultsThe incidence of BTCP in patients with cancer decreased from 42% to 23% (19% reduction), the accuracy of the pain score evaluation increased from 84% to 95% (11% increase), and satisfaction with pain control increased from 80% to 94% (14% increase). The average pain and BTCP scores of patients with cancer pain significantly improved (<i>P</i><0.05).ConclusionsThe nurse-led cancer pain management model may play a positive role, suggesting potential benefits in reducing the incidence of BTCP, effectively controlling the average pain score, and enhancing patient satisfaction with pain management.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261472063"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Prospective Phase II Study of Induction Therapy With Pembrolizumab, Cisplatin, and Fluorouracil in Patients With Locally Advanced Head and Neck Cancer.","authors":"Ilya Pokataev, Olesia Stativko, Margarita Nosova, Sergey Kravtsov, Luidmila Zhukova, Daniil Stroyakovskiy, Emil Sabitov, Evgeniya Kuzmina, Polina Feoktistova, Tatiana Antonova, Marina Lyadova, Rozanna Sydykova, Kristina Lisitsyna, Tatiana Strelnikova, Gulnara Alizade, Sergey Parts, Magomed Dolov, Anna Tedeeva, Sergei Iugai, Vsevolod Galkin","doi":"10.1177/10732748261452332","DOIUrl":"10.1177/10732748261452332","url":null,"abstract":"<p><p>BackgroundThe approved induction chemotherapy regimen with docetaxel, cisplatin, and 5-fluorouracil is associated with a high risk of severe toxicity, which may compromise the feasibility of subsequent chemoradiation. Safer and more effective induction strategies are needed for patients with unresectable locally advanced head and neck squamous cell carcinoma (HNSCC).MethodsWe aimed to evaluate the feasibility, efficacy, and safety of induction immunochemotherapy followed by (chemo)radiation in patients with unresectable locally advanced HNSCC. In this prospective, multicenter, non-randomized phase II trial, patients with PD-L1-positive (Combined Positive Score ≥1) locally advanced squamous cell carcinoma of the oropharynx, larynx, or hypopharynx and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 received three 21-day cycles of pembrolizumab, cisplatin, and 5-fluorouracil, followed by chemoradiotherapy or radiotherapy in the absence of disease progression.ResultsAmong 120 enrolled patients, 116 were evaluable for response. The objective response rate after induction therapy was 62.9%, including 16.4% complete responses. After a median follow-up of 26 months, the 2-year PFS and OS rates were 53.0% and 65.1%, respectively. Grade 3-4 adverse events occurred in 30.8% of patients, with neutropenia reported in 23.3% and febrile neutropenia in 1.7%. Immune-related events were infrequent and mild (skin rash: 1.7%; hypothyroidism: 0.8%). No treatment-related deaths occurred.ConclusionsInduction immunochemotherapy with pembrolizumab, cisplatin, and fluorouracil demonstrated encouraging efficacy, manageable toxicity, and high transition and completion rates of chemoradiation. These findings should be considered hypothesis-generating rather than practice-changing and require confirmation in a randomized trial.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261452332"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making PRO Data Work: Remote Monitoring, Real-Time Visualization, and Timely Intervention in Oncology Trials and Patient Care.","authors":"Bill Byrom, Anthony Everhart","doi":"10.1177/10732748261492633","DOIUrl":"10.1177/10732748261492633","url":null,"abstract":"<p><p>Clinician assessment of adverse events in oncology systematically underestimates the severity and frequency of symptoms that patients actually experience, creating risks in both drug development and routine care. Electronic patient-reported outcome (ePRO) systems help to address this gap by enabling frequent remote symptom monitoring, bringing the patient voice into the care pathway between clinic visits. Published studies confirm that automated data-driven alerting in response to ePRO data entries can drive better patient outcomes including reduced emergency department visits, delayed physical function deterioration, and improved symptom control, with early intervention the likely mechanism. Translating this evidence into practice demands deliberate attention to how data are visualized, communicated, and acted upon. This perspectives article examines, primarily in the context of oncology clinical trials, the tools and design principles that translate ePRO data into timely clinical action, including heatmap visualizations that reveal symptom trajectories at a glance, predefined alert thresholds that trigger proactive responses, and patient-facing self-management support delivered at the moment of reporting. The regulatory, ethical and methodological case for embedding active monitoring within oncology trial design is also considered.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261492633"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretable Machine Learning for Survival Prediction in Small Cell Lung Cancer Patients With Brain Metastases: A Population-Based Study With External Validation.","authors":"Ning Luo, Shifan Tan, Xiaocai Li, Si Liu, Shangyu Xie, Xiaoying Huang, Dong Wu","doi":"10.1177/10732748261419190","DOIUrl":"10.1177/10732748261419190","url":null,"abstract":"<p><p>IntroductionBrain metastases (BM) represent a common and fatal progression in small cell lung cancer (SCLC), yet prognostic tools for this population remain underdeveloped. This study aimed to establish and externally validate a machine learning-based model to predict overall survival (OS) in SCLC patients with BM.MethodsWe extracted clinical data from 2392 SCLC patients with BM from the SEER database to construct prognostic models using Cox regression, AJCC staging, and four machine learning algorithms: Random Survival Forest (RSF), Extreme Gradient Boosting (XGB), Elastic Net (Enet), and Artificial Neural Network (ANN). Key features were selected via Lasso-Cox regression. Model performance was evaluated using time-dependent AUC, calibration curves, Brier scores, precision-recall (PR) curves, and decision curve analysis (DCA). SHAP and partial dependence plots were applied for model interpretability. External validation was conducted using an independent hospital-based cohort of 85 patients, with comparability to the SEER cohort addressed through inverse probability of treatment weighting (IPTW).ResultsAmong all models, the RSF algorithm demonstrated the best overall performance. In the training cohort, it achieved AUCs of 0.738 and 0.809 for 1-year and 2-year OS, respectively. In the internal validation cohort, AUCs were 0.718 and 0.748, and in the external validation cohort, 0.686 and 0.802, respectively. The RSF model also showed favorable calibration and the lowest Brier scores across datasets. SHAP analysis ranked chemotherapy, liver metastasis, N stage, and age as the most influential prognostic features. A web-based calculator was developed to enable real-time individualized risk prediction.ConclusionsThis study presents a robust, interpretable, and externally validated RSF-based model for predicting OS in SCLC patients with BM. The model offers clinically relevant insights and is accessible via an online tool, supporting its potential integration into personalized treatment planning.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261419190"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Late and Long-Term Effects Among Swedish Adolescents and Young Adults Affected by Cancer Following a Wilderness Intervention: Reconnecting with Self and Meaning Through Nature's Unconditional Presence - A Qualitative Study.","authors":"Heléne Dahlqvist, Ann Ekdahl, Emma Wiklund, Mats Jong, Sveinung Berntsen, Carina Ribe Fernee, Miek C Jong","doi":"10.1177/10732748251414202","DOIUrl":"10.1177/10732748251414202","url":null,"abstract":"<p><p>IntroductionAdolescents and Young Adults (AYAs) affected by cancer are at risk of experiencing late and long-term effects following cancer diagnosis and treatment. While structured interventions have demonstrated potential benefits for well-being during the intervention itself, little is known about how AYAs affected by cancer engage with and experience nature in their everyday lives beyond the formal program context. The aim of this study was to explore how a selected group of AYAs affected by cancer-who had participated in a nature-based intervention (the WAYA program)-experience nature and its role in supporting and managing late and long-term effects of cancer and its treatment, beyond the context of the program itself.MethodThis qualitative study explored the experiences of nature following the WAYA intervention among AYAs affected by cancer. Data were collected by focus group interviews at a three-month follow-up, using participant-selected photographs as visual prompts to elicit reflection on how nature supports management of late and long-term effects of cancer. A photovoice-inspired approach guided discussion questions and facilitated individual and collective meaning-making. Interviews were audio-recorded, transcribed verbatim, and analyzed using qualitative content analysis.ResultsThe analysis of this study showed one theme: Reconnecting with self and meaning through nature's unconditional presence-beyond human connection. The theme comprises the two categories <i>Nature as a resource for inner balance</i> and <i>Nature as a meaningful companion</i>, and five sub-categories<i>: Managing by being mindful, Managing by experiencing rest and being calm, Experiencing metaphoric recognition, Sparking comfort, hope and positive emotions,</i> and <i>Nature as a space without obligations.</i>ConclusionThis study explored how AYAs affected by cancer engage with nature beyond formal programs, revealing its potential in better management of late and long-term effects. These findings can inform low-threshold, personal meaningful, and sustainable approaches to clinical practice, well-being, and rehabilitation for this vulnerable group.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251414202"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12827910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer.","authors":"","doi":"10.1177/10732748261476405","DOIUrl":"10.1177/10732748261476405","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261476405"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148921533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Correcting Misinformation is Challenging\": Exploring Barriers and Facilitators of Health Care Providers' Responsiveness to Cervical Cancer Screening Literacy Needs of Rural Women Living With HIV in Eastern Uganda.","authors":"Juliana Namutundu, Edith Nakku-Joloba, Juliet Kiguli, Fredrick Makumbi, Fred C Semitala, Rhoda K Wanyenze, Miriam Laker-Oketta, Damalie Nakanjako, Miriam Nakalembe","doi":"10.1177/10732748261419591","DOIUrl":"10.1177/10732748261419591","url":null,"abstract":"<p><p>IntroductionCervical cancer screening literacy among rural women living with HIV (WLHIV), the ability to access, understand, appraise, and apply cervical cancer screening information to use cervical cancer screening services, is affected by individual factors including low educational attainment, low socioeconomic status, poor cervical cancer risk perception, fear, misconceptions, and beliefs, as well as interpersonal, community, and health facility barriers. However, rural public health facilities have limited resources that limit their ability mitigate these challenges. This research identified barriers and facilitators of healthcare providers' responsiveness to cervical cancer screening literacy needs of rural WLHIV in Eastern Uganda.MethodsThis was a descriptive qualitative study that involved conducting 15 Key Informant Interviews with all individuals involved in planning, communicating, and providing cervical cancer screening services at 4 purposively selected rural public health facilities in Eastern Uganda. Data were collected using a guide developed based on the organizational Health Literacy responsiveness framework. This framework was used to derive deductive categories (domains and sub-domains) during thematic analysis, and barriers and facilitators were inductively identified from the interviews.ResultsBarriers included non-involvement of health workers and affected women in planning, limited funding, few trained health workers, long waiting times, limited space, limited communication modalities, inadequate Information Education and Communication (IEC) materials, IEC materials not translated to the local language, challenges with addressing misconceptions, and language barriers. Facilitators included support from implementing partners, free cervical cancer screening services, integration of cervical cancer screening into HIV care, consumer-centered care, clear pathways and navigation support, using peers during health education, availability of IEC materials, using simple, local language during education sessions, and health worker facilitation.ConclusionStrategies targeted at the identified factors can improve health care providers' responsiveness to the cervical cancer screening literacy needs of rural WLHIV in Eastern Uganda.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261419591"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited English Proficiency and Self-Reported Lifetime Use of Colorectal Cancer Screening Tests Among Asian Origin Groups in California: A Cross-Sectional Study.","authors":"Meng-Han Tsai, Steven S Coughlin, Alice W Lee, Minjee Lee, Haidong Zhu, Xiaoling Wang, Shaoyong Su, Yanbin Dong, Daramola N Cabral, Milkie Vu","doi":"10.1177/10732748261494374","DOIUrl":"https://doi.org/10.1177/10732748261494374","url":null,"abstract":"<p><p>IntroductionAsian Americans have lower colorectal cancer (CRC) screening rates compared with other racial/ethnic groups in the United States (U.S.). Moreover, individuals with limited English proficiency (LEP) face additional challenges in understanding and accessing healthcare. We examined the association between seven Asian origin groups and lifetime use of CRC screening [home fecal occult blood test (FOBT) and endoscopy], stratified by LEP status.MethodsData from the 2021-2022 California Health Interview Survey were analyzed (n=23,785 respondents aged 50-75 years). Asian origin groups (Chinese, Filipino, Japanese, Korean, South Asian, Vietnamese, Others) and LEP were exposures of interest. Ever having lifetime use of FOBT and endoscopy screening were outcomes of interest. Weighted multivariable logistic regression was performed.ResultsThe highest prevalence of FOBT screening use were observed in Vietnamese respondents with LEP (57.6%); however, the lowest prevalence of FOBT screening use was found among Filipino (16.6%) respondents with LEP (p-value=0.014). In adjusted analysis, Chinese and Filipino with LEP had 50% (OR, 0.50; 95%, 0.28-0.90) and 90% (OR, 0.10; 95%, 0.03-0.27) lower odds of having lifetime FOBT use, respectively. For those without LEP, South Asians had 46% (OR, 0.54; 95%, 0.38-0.77) lower odds of having lifetime FOBT use, and Chinese and Korean had 35% (OR, 0.65; 95%, 0.51-0.84) and 52% (OR, 0.48; 95%, 0.33-0.69) lower odds of having lifetime endoscopy use, respectively.ConclusionFOBT screening disparities are evident among Chinese and Filipino Americans with LEP. These findings highlight the complexity of CRC screening disparities across Asian origin groups and suggest the need for further investigation.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261494374"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U.S. Cancer-Specific Mortality Trends After Early Immune Checkpoint Inhibitor Approvals: An Ecological Synthetic-Control Study, 1999-2019.","authors":"Woo Joo Lee, Seon Hye Won, Robin Park, Muhammad Sohaib Asghar, Moazzam Shahzad, Thomas Shimshak","doi":"10.1177/10732748261492471","DOIUrl":"10.1177/10732748261492471","url":null,"abstract":"<p><p>IntroductionImmune checkpoint inhibitors (ICIs) were introduced at different times across cancer types, but whether early approvals coincided with cancer-specific changes in national mortality remains uncertain.MethodsWe conducted an ecological observational comparative time-series study using CDC WONDER United States Cancer Statistics mortality data from 1999-2019. We analyzed CDC-calculated age-adjusted mortality rates (AAMRs) for melanoma of the skin, lung and bronchus, kidney and renal pelvis, urinary bladder, and Hodgkin lymphoma. Cancer-specific synthetic-control models used each site's first major ICI approval year, preperiod-centered log AAMR trajectories, mutually exclusive solid or hematologic comparison sites, and a common 0-3-year postapproval estimand. Placebo analyses and staggered-adoption difference-in-differences (DiD) were robustness checks.ResultsObserved AAMRs averaged 3.44%, 13.05%, 4.73%, 3.60%, and 3.68% below synthetic estimates for melanoma, lung, kidney, bladder, and Hodgkin lymphoma, respectively. Conditional placebo-rank pseudo-P values were .40, .23, .25, .20, and 1.00. Temporal-placebo models showed earlier divergence for several sites. The balanced 0-3-year DiD estimate was -0.96 deaths per 100,000 (95% pointwise CI, -2.99 to 1.06).ConclusionCancer-specific mortality patterns were directionally compatible with lower mortality during early ICI approval eras, but placebo benchmarking, heterogeneous temporal specificity, and an imprecise DiD estimate precluded firm causal attribution. These ecological findings do not estimate individual treatment effectiveness or current ICI practice.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261492471"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary and Urinary Iodine in Relation to Thyroid Cancer Risk: A Meta-Analysis.","authors":"Shitao Li, Hengxu Yu","doi":"10.1177/10732748261419192","DOIUrl":"10.1177/10732748261419192","url":null,"abstract":"<p><p>IntroductionThe influence of iodine on papillary thyroid carcinoma (PTC) remains a subject of debate. This meta-analysis was conducted to evaluate the risk association between varying levels of iodine intake and the occurrence of PTC and different subtypes of thyroid carcinoma (TC), particularly papillary thyroid microcarcinoma (PTMC).MethodsFour databases-the Cochrane Library, Embase, PubMed, and Web of Science-were systematically searched for relevant studies published up until May 30, 2024. An updated search was conducted on November 20, 2025. Literature screening and information collection were performed according to predefined eligibility criteria. The Newcastle-Ottawa Scale (NOS) was used to appraise the quality of the eligible literature. Statistical analysis was performed using Stata 17.ResultsThis meta-analysis encompassed 17 studies involving 273 651 individuals. The findings revealed a correlation between high urinary iodine concentrations and an increased risk of TC (odds ratio [OR]: 6.43, 95% confidence interval [CI]: 2.72-15.22, <i>P</i> < .05). The elevated risk was observed for both PTC (OR: 7.56, 95% CI: 1.6-35.78, <i>P</i> < .001) and PTMC (OR: 8.96, 95% CI: 5.89-13.64, <i>P</i> < .001). These results suggested that greater urinary iodine concentrations were associated with a higher risk of TC. However, there was no significant association between dietary iodine intake and TC risk (OR: 0.75, 95% CI: 0.37-1.52, <i>P</i> > .05).ConclusionThis meta-analysis demonstrated a definitive link between high urinary iodine excretion and an increased risk of TC. The relationship between dietary iodine intake and TC requires further investigation. Considering the current limitations, future large-scale, multicenter, prospective investigations are anticipated to provide further validation.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261419192"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}